| Biomarker ID | 1221 |
| PMID | 24115268 |
| Year | 2014 |
| Biomarker | β-Microseminoprotein |
| Biomarker Basis | Expression Based |
| Biomolecule | Protein |
| Source | Urine |
| Subjects | Humans |
| Regulation | Downregulated in PCa |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | NA |
| Experiment | Prostate Cancer Vs Other Prostatic Conditions |
| Type of Biomarker | Diagnostic |
| Cohort | 25 participants with prostate cancer (PCa) and 27 participants with a variety of benign prostatic conditions [BPH( n=11), Prostatitis (n=20), Atrophy (n=12)]were included in the study. [Non cancer prostatis conditions were overlapping for patients] |
| Senstivity | NA |
| Specificity | NA |
| AUC | 0.6978 |
| Accuracy | NA |
| Level Of Significance | p = 0.01 |
| Method Used | MALDI- MS |
| Clinical | No |
| Remarks | A peak at m/z 10,760 was identified as b-microseminoprotein (b-MSMB) |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | MSMB |